SynthesisCold Spring Harbor molecular case studies2019
Implementation of cancer next-generation sequencing testing in a community hospital.
Synthesis in Cold Spring Harbor molecular case studies, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Barriers and facilitators to next-generation sequencing use in United States oncology settings: a systematic review.Future oncology (London, England) · 2024Pooled it
- Analytical and clinical validation of CancerMaster, an automated targeted NGS panel, for tumor-only precision oncology.Scientific reports · 2026Article
- Precision medicine in orthopaedics: A review of current technologies and future directions.Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA · 2026Review
- A novel one-step multiplex PCR method (OS-MPCR) for efficient NGS library preparation in cancer.PloS one · 2026Article
- Liquid Biopsy and Automated Next-Generation Sequencing: Achieving Results in 27 Hours Within a Community Setting.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Circulating tumor DNA in patients with cancer: insights from clinical laboratory.Advances in laboratory medicine · 2025Review
- Understanding the Landscape of Cancer Care in Europe: Evaluating Clinical and Comprehensive Cancer Centers.Healthcare (Basel, Switzerland) · 2024Article
- Understanding inequities in precision oncology diagnostics.Nature cancer · 2023Review
- Toward a More Just System of Care in Molecular Pathology.The Milbank quarterly · 2022Article
- Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network.The oncologist · 2022Article
- Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe.Journal of personalized medicine · 2022Article
- Single-Cell Analysis Using Machine Learning Techniques and Its Application to Medical Research.Biomedicines · 2021Review
- Application of Next Generation Sequencing in Laboratory Medicine.Annals of laboratory medicine · 2021Review
- Quality assessment of a clinical next-generation sequencing melanoma panel within the Italian Melanoma Intergroup (IMI).Diagnostic pathology · 2020Article
- Article
- PCR inhibition in qPCR, dPCR and MPS-mechanisms and solutions.Analytical and bioanalytical chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the current era of personalized medicine, the field of oncology is witnessing a paradigm shift in patient care that is driving a tighter integration of genomic analysis modalities in patient care decision. This is driven by the expanding category of targeted therapies that require a broader understanding of the mutational profile of patient samples to more precisely guided personalized treatment decisions. Next-generation sequencing (NGS) has proved to be of tremendous power in detecting and characterizing a broad spectrum of activating or loss-of-function mutations across many gene targets. This power of NGS also results in significant challenges related to technical expertise, bioinformatics, computing infrastructure, laboratory practices, and integration into clinical decision-making. These challenges are particularly relevant to smaller and mid-tier hospital networks that are faced with the need to modernize their clinical practices and offer their patients access to advanced genomic technologies to improve outcomes. Adoption of such personalized medicine relies on information about a patient's cancer genome and the identification of its variants. This is best achieved using NGS. However, there are challenges to the adoption of such a complex technology and workflow, especially in smaller hospital systems. This commentary summarizes key considerations and challenges related to implementation of NGS in a community hospital setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.